<b>Background and Aims:</b> This study was aim to investigate the relationship between the four intron SNPs (rs3087404, rs2029167, rs2029166 and rs7296239) of SMUG1 and the susceptibility of cervical squamous cell carcinoma.
<b>Conclusion:</b> Beyond HK2 expression, <sup>18</sup>F-FDG negativity in (mainly pretreated) MM patients seems to be associated with additional causes not yet known.
<b>Conclusion:</b> Brain <sup>18</sup>F-FDG PET/CT may play a significant role in the initial evaluation of patients with clinically suspected antibody-mediated autoimmune encephalitis.
<b>Conclusion:</b> In vivo metabolic tumor profiling in patients with PPGL can be achieved by assessing <sup>18</sup>F-FDG pharmacokinetics using dynamic PET/CT scanning.
<b>Conclusion:</b> Independent-component analysis of <sup>18</sup>F-FDG PET data showed a gradual disruption of functional brain connectivity with progression of cognitive decline in AD.
<b>Conclusion:</b> Independent-component analysis of <sup>18</sup>F-FDG PET data showed a gradual disruption of functional brain connectivity with progression of cognitive decline in AD.
<b>Conclusion:</b> Performing <sup>18</sup>F-FDG PET for early evaluation of response often results in a change of management in GIST patients harboring the non-<i>KIT</i> exon 11 mutation and should be considered the standard of care in GIST patients treated with neoadjuvant intent.
<b>Conclusion:</b> Pretherapeutic <sup>18</sup>F-FDG PET/CT provides prognostic information in patients with advanced MTC scheduled for treatment with the TKI vandetanib.
<b>Conclusion:</b> Standard <sup>18</sup>F-FDG PET/CT is an effective preoperative imaging method for the prediction of LN status in VC, allowing the prediction of pathologically negative groins and thus the selection of patients suitable for minimally invasive surgery.
<b>Conclusion:</b> Standard <sup>18</sup>F-FDG PET/CT is an effective preoperative imaging method for the prediction of LN status in VC, allowing the prediction of pathologically negative groins and thus the selection of patients suitable for minimally invasive surgery.
<b>Conclusion:</b> The feasibility of <sup>18</sup>F-FDG PET/MRI for diagnosing pain generators in chronic sciatica was demonstrated, revealing various possible etiologies.
<b>Conclusion:</b> The identification of additional lesions outside the R-FOV (eyes to thighs) using <sup>18</sup>F-FDG PET/CT has no impact in the definition of the clinical stage of disease and minimal impact in the treatment definition of patients with pediatric lymphoma.
<b>Conclusion:</b> This meta-analysis of available studies demonstrates that whole-body <sup>18</sup>F-FDG PET or <sup>18</sup>F-FDG PET/CT has high diagnostic accuracy and moderate to high sensitivity and specificity for detection of underlying malignancy in patients suspected of having a paraneoplastic syndrome.
<b>Conclusion:</b> We confirmed that <sup>18</sup>F-FDG PET scanning is a reliable tool for BMI assessment in HL, and BM biopsy is no longer needed for routine staging.
<b>Conclusion:</b> We confirmed that <sup>18</sup>F-FDG PET scanning is a reliable tool for BMI assessment in HL, and BM biopsy is no longer needed for routine staging.
<b>Conclusion:</b> We confirmed that <sup>18</sup>F-FDG PET scanning is a reliable tool for BMI assessment in HL, and BM biopsy is no longer needed for routine staging.
<b>Conclusion:</b> We showed that two radiomic features derived from FDG PET were independently associated with LC in patients with NSCLC undergoing SBRT and could be combined in an accurate predictive model.
<b>Conclusion:</b><sup>18</sup>F-FDG PET/CT after 1 treatment cycle is predictive of outcome to first-line chemotherapy with bevacizumab in patients with advanced nonsquamous NSCLC.
<b>Conclusion:</b><sup>18</sup>F-FDG PET response to induction chemotherapy could be a useful imaging biomarker to identify patients with esophageal adenocarcinoma who could benefit from subsequent esophagectomy after chemoradiotherapy.
<b>Conclusion:</b><sup>18</sup>F-FDG PET/CT revealed previously unsuspected distant metastases in 16% of male patients with pre-PET/CT stage IIB breast cancer and 33% of those with stage III breast cancer.
<b>Conclusion:</b><sup>18</sup>F-FDG PET/CT revealed previously unsuspected distant metastases in 16% of male patients with pre-PET/CT stage IIB breast cancer and 33% of those with stage III breast cancer.
<b>Conclusion:</b><sup>18</sup>F-FDG PET/CT revealed previously unsuspected distant metastases in 16% of male patients with pre-PET/CT stage IIB breast cancer and 33% of those with stage III breast cancer.